1	Addiction	_	_	NN	_	_	_	_	_
2	represents	_	_	VBZ	_	_	_	_	_
3	an	_	_	DT	_	_	_	_	_
4	enormous	_	_	JJ	_	_	_	_	_
5	challenge	_	_	NN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	society	_	_	NN	_	_	_	_	_
8	.	_	_	.	_	_	_	_	_


1	Worldwide	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	it	_	_	PRP	_	_	_	_	_
4	has	_	_	VBZ	_	_	_	_	_
5	been	_	_	VBN	_	_	_	_	_
6	estimated	_	_	VBN	_	_	_	_	_
7	that	_	_	IN	_	_	_	_	_
8	alcohol	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	tobacco	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	illicit	_	_	JJ	_	_	_	_	_
14	drugs	_	_	NNS	_	_	_	_	_
15	were	_	_	VBD	_	_	_	_	_
16	responsible	_	_	JJ	_	_	_	_	_
17	for	_	_	IN	_	_	_	_	_
18	more	_	_	JJR	_	_	_	_	_
19	than	_	_	IN	_	_	_	_	_
20	10	_	_	CD	_	_	_	_	_
21	million	_	_	CD	_	_	_	_	_
22	deaths	_	_	NNS	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	with	_	_	IN	_	_	_	_	_
25	a	_	_	DT	_	_	_	_	_
26	higher	_	_	JJR	_	_	_	_	_
27	impact	_	_	NN	_	_	_	_	_
28	in	_	_	IN	_	_	_	_	_
29	developed	_	_	VBN	_	_	_	_	_
30	countries	_	_	NNS	_	_	_	_	_
31	where	_	_	WRB	_	_	_	_	_
32	substance	_	_	NN	_	_	_	_	_
33	use	_	_	NN	_	_	_	_	_
34	disorders	_	_	NNS	_	_	_	_	_
35	have	_	_	VBP	_	_	_	_	_
36	been	_	_	VBN	_	_	_	_	_
37	identified	_	_	VBN	_	_	_	_	_
38	as	_	_	IN	_	_	_	_	_
39	responsible	_	_	JJ	_	_	_	_	_
40	for	_	_	IN	_	_	_	_	_
41	life	_	_	NN	_	_	_	_	_
42	expectancy	_	_	NN	_	_	_	_	_
43	reversals	_	_	NNS	_	_	_	_	_
44	.	_	_	.	_	_	_	_	_


1	Societal	_	_	JJ	_	_	_	_	_
2	and	_	_	CC	_	_	_	_	_
3	medical	_	_	JJ	_	_	_	_	_
4	responses	_	_	NNS	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	problem	_	_	NN	_	_	_	_	_
8	are	_	_	VBP	_	_	_	_	_
9	far	_	_	RB	_	_	_	_	_
10	from	_	_	IN	_	_	_	_	_
11	optimal	_	_	JJ	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	but	_	_	CC	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	appearance	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	new	_	_	JJ	_	_	_	_	_
18	technologies	_	_	NNS	_	_	_	_	_
19	offers	_	_	VBZ	_	_	_	_	_
20	room	_	_	NN	_	_	_	_	_
21	for	_	_	IN	_	_	_	_	_
22	improvement	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	with	_	_	IN	_	_	_	_	_
25	lots	_	_	NNS	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	new	_	_	JJ	_	_	_	_	_
28	initiatives	_	_	NNS	_	_	_	_	_
29	launched	_	_	VBN	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	developed	_	_	VBN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	special	_	_	JJ	_	_	_	_	_
3	issue	_	_	NN	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	intended	_	_	VBN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	describe	_	_	VB	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	discuss	_	_	VB	_	_	_	_	_
10	how	_	_	WRB	_	_	_	_	_
11	these	_	_	DT	_	_	_	_	_
12	new	_	_	JJ	_	_	_	_	_
13	tools	_	_	NNS	_	_	_	_	_
14	are	_	_	VBP	_	_	_	_	_
15	helping	_	_	VBG	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	improve	_	_	VB	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	assessment	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	treatment	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	such	_	_	JJ	_	_	_	_	_
24	old	_	_	JJ	_	_	_	_	_
25	problems	_	_	NNS	_	_	_	_	_
26	(	_	_	-LRB-	_	_	_	_	_
27	addictive	_	_	JJ	_	_	_	_	_
28	disorders	_	_	NNS	_	_	_	_	_
29	)	_	_	-RRB-	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	covering	_	_	VBG	_	_	_	_	_
32	a	_	_	DT	_	_	_	_	_
33	wide	_	_	JJ	_	_	_	_	_
34	diversity	_	_	NN	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	novelties	_	_	NNS	_	_	_	_	_
37	that	_	_	WDT	_	_	_	_	_
38	are	_	_	VBP	_	_	_	_	_
39	being	_	_	VBG	_	_	_	_	_
40	applied	_	_	VBN	_	_	_	_	_
41	in	_	_	IN	_	_	_	_	_
42	the	_	_	DT	_	_	_	_	_
43	field	_	_	NN	_	_	_	_	_
44	.	_	_	.	_	_	_	_	_


1	Digital	_	_	JJ	_	_	_	_	_
2	health	_	_	NN	_	_	_	_	_
3	entails	_	_	VBZ	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	possibility	_	_	NN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	overcome	_	_	VB	_	_	_	_	_
8	existent	_	_	JJ	_	_	_	_	_
9	problems	_	_	NNS	_	_	_	_	_
10	around	_	_	IN	_	_	_	_	_
11	addictive	_	_	JJ	_	_	_	_	_
12	disorders	_	_	NNS	_	_	_	_	_
13	like	_	_	IN	_	_	_	_	_
14	stigmatization	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	addiction	_	_	NN	_	_	_	_	_
17	identification	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	treatment	_	_	NN	_	_	_	_	_
20	access	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	adherence	_	_	NN	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	treatment	_	_	NN	_	_	_	_	_
25	efficacy	_	_	NN	_	_	_	_	_
26	by	_	_	IN	_	_	_	_	_
27	facilitating	_	_	VBG	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	improvement	_	_	NN	_	_	_	_	_
30	in	_	_	IN	_	_	_	_	_
31	knowledge	_	_	NN	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	assessment	_	_	NN	_	_	_	_	_
34	,	_	_	,	_	_	_	_	_
35	diagnosis	_	_	NN	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	and	_	_	CC	_	_	_	_	_
38	treatment	_	_	NN	_	_	_	_	_
39	of	_	_	IN	_	_	_	_	_
40	addictive	_	_	JJ	_	_	_	_	_
41	disorders	_	_	NNS	_	_	_	_	_
42	.	_	_	.	_	_	_	_	_


1	Assessment	_	_	NN	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	one	_	_	CD	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	areas	_	_	NNS	_	_	_	_	_
7	where	_	_	WRB	_	_	_	_	_
8	new	_	_	JJ	_	_	_	_	_
9	solutions	_	_	NNS	_	_	_	_	_
10	have	_	_	VBP	_	_	_	_	_
11	probably	_	_	RB	_	_	_	_	_
12	reached	_	_	VBN	_	_	_	_	_
13	furthest	_	_	JJS	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Think	_	_	VB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	for	_	_	IN	_	_	_	_	_
4	example	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	about	_	_	IN	_	_	_	_	_
7	transdermal	_	_	JJ	_	_	_	_	_
8	sensors	_	_	NNS	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	ecological	_	_	JJ	_	_	_	_	_
11	momentary	_	_	JJ	_	_	_	_	_
12	assessment	_	_	NN	_	_	_	_	_
13	:	_	_	:	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	clear	_	_	JJ	_	_	_	_	_
16	example	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	how	_	_	WRB	_	_	_	_	_
19	new	_	_	JJ	_	_	_	_	_
20	technologies	_	_	NNS	_	_	_	_	_
21	can	_	_	MD	_	_	_	_	_
22	reach	_	_	VB	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	core	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	a	_	_	DT	_	_	_	_	_
27	patient	_	_	NN	_	_	_	_	_
28	’s	_	_	POS	_	_	_	_	_
29	drinking	_	_	NN	_	_	_	_	_
30	pattern	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	special	_	_	JJ	_	_	_	_	_
4	issue	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	Barrio	_	_	NNP	_	_	_	_	_
7	et	_	_	FW	_	_	_	_	_
8	al.	_	_	FW	_	_	_	_	_
9	investigate	_	_	VB	_	_	_	_	_
10	patients	_	_	NNS	_	_	_	_	_
11	’	_	_	POS	_	_	_	_	_
12	attitudes	_	_	NNS	_	_	_	_	_
13	towards	_	_	IN	_	_	_	_	_
14	transdermal	_	_	JJ	_	_	_	_	_
15	sensors	_	_	NNS	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	real	_	_	JJ	_	_	_	_	_
18	clinical	_	_	JJ	_	_	_	_	_
19	settings	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Digital	_	_	JJ	_	_	_	_	_
2	technologies	_	_	NNS	_	_	_	_	_
3	might	_	_	MD	_	_	_	_	_
4	be	_	_	VB	_	_	_	_	_
5	useful	_	_	JJ	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	assess	_	_	VB	_	_	_	_	_
8	brain	_	_	NN	_	_	_	_	_
9	damage	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	they	_	_	PRP	_	_	_	_	_
13	bring	_	_	VBP	_	_	_	_	_
14	us	_	_	PRP	_	_	_	_	_
15	closer	_	_	RBR	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	understanding	_	_	VBG	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	mechanism(s)	_	_	NN	_	_	_	_	_
20	underlying	_	_	VBG	_	_	_	_	_
21	addiction	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_
23	Herreros	_	_	NNP	_	_	_	_	_
24	et	_	_	FW	_	_	_	_	_
25	al.	_	_	FW	_	_	_	_	_
26	present	_	_	VB	_	_	_	_	_
27	a	_	_	DT	_	_	_	_	_
28	visuomotor	_	_	NN	_	_	_	_	_
29	rotation	_	_	NN	_	_	_	_	_
30	task	_	_	NN	_	_	_	_	_
31	which	_	_	WDT	_	_	_	_	_
32	might	_	_	MD	_	_	_	_	_
33	be	_	_	VB	_	_	_	_	_
34	the	_	_	DT	_	_	_	_	_
35	first	_	_	JJ	_	_	_	_	_
36	step	_	_	NN	_	_	_	_	_
37	towards	_	_	IN	_	_	_	_	_
38	developing	_	_	VBG	_	_	_	_	_
39	a	_	_	DT	_	_	_	_	_
40	useful	_	_	JJ	_	_	_	_	_
41	tool	_	_	NN	_	_	_	_	_
42	for	_	_	IN	_	_	_	_	_
43	the	_	_	DT	_	_	_	_	_
44	detection	_	_	NN	_	_	_	_	_
45	of	_	_	IN	_	_	_	_	_
46	cerebellum	_	_	NN	_	_	_	_	_
47	dysfunction	_	_	NN	_	_	_	_	_
48	by	_	_	IN	_	_	_	_	_
49	assessing	_	_	VBG	_	_	_	_	_
50	alterations	_	_	NNS	_	_	_	_	_
51	in	_	_	IN	_	_	_	_	_
52	implicit	_	_	JJ	_	_	_	_	_
53	learning	_	_	NN	_	_	_	_	_
54	among	_	_	IN	_	_	_	_	_
55	chronic	_	_	JJ	_	_	_	_	_
56	cannabis	_	_	NN	_	_	_	_	_
57	users	_	_	NNS	_	_	_	_	_
58	.	_	_	.	_	_	_	_	_


1	New	_	_	JJ	_	_	_	_	_
2	technologies	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	opened	_	_	VBN	_	_	_	_	_
5	up	_	_	RP	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	possibility	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	not	_	_	RB	_	_	_	_	_
10	only	_	_	RB	_	_	_	_	_
11	assessing	_	_	VBG	_	_	_	_	_
12	patients	_	_	NNS	_	_	_	_	_
13	“	_	_	``	_	_	_	_	_
14	right	_	_	RB	_	_	_	_	_
15	here	_	_	RB	_	_	_	_	_
16	right	_	_	RB	_	_	_	_	_
17	now	_	_	RB	_	_	_	_	_
18	”	_	_	''	_	_	_	_	_
19	but	_	_	CC	_	_	_	_	_
20	also	_	_	RB	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	creating	_	_	VBG	_	_	_	_	_
23	new	_	_	JJ	_	_	_	_	_
24	realities	_	_	NNS	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	or	_	_	CC	_	_	_	_	_
27	should	_	_	MD	_	_	_	_	_
28	we	_	_	PRP	_	_	_	_	_
29	better	_	_	RBR	_	_	_	_	_
30	say	_	_	VB	_	_	_	_	_
31	virtual	_	_	JJ	_	_	_	_	_
32	realities	_	_	NNS	_	_	_	_	_
33	?	_	_	.	_	_	_	_	_
34	Ghiţă	_	_	FW	_	_	_	_	_
35	et	_	_	FW	_	_	_	_	_
36	al.	_	_	FW	_	_	_	_	_
37	show	_	_	VB	_	_	_	_	_
38	us	_	_	PRP	_	_	_	_	_
39	that	_	_	IN	_	_	_	_	_
40	virtual	_	_	JJ	_	_	_	_	_
41	reality	_	_	NN	_	_	_	_	_
42	can	_	_	MD	_	_	_	_	_
43	enhance	_	_	VB	_	_	_	_	_
44	the	_	_	DT	_	_	_	_	_
45	assessment	_	_	NN	_	_	_	_	_
46	of	_	_	IN	_	_	_	_	_
47	alcohol-induced	_	_	JJ	_	_	_	_	_
48	craving	_	_	NN	_	_	_	_	_
49	and	_	_	CC	_	_	_	_	_
50	anxiety	_	_	NN	_	_	_	_	_
51	.	_	_	.	_	_	_	_	_


1	Technological	_	_	JJ	_	_	_	_	_
2	advances	_	_	NNS	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	neuroimaging	_	_	NN	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	genetics	_	_	NNS	_	_	_	_	_
7	have	_	_	VBP	_	_	_	_	_
8	allowed	_	_	VBN	_	_	_	_	_
9	deepening	_	_	VBG	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	understanding	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	some	_	_	DT	_	_	_	_	_
15	learning	_	_	NN	_	_	_	_	_
16	processes	_	_	NNS	_	_	_	_	_
17	involved	_	_	VBN	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	substance	_	_	NN	_	_	_	_	_
20	use	_	_	NN	_	_	_	_	_
21	disorders	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_
23	Garbusow	_	_	NNP	_	_	_	_	_
24	et	_	_	FW	_	_	_	_	_
25	al.	_	_	FW	_	_	_	_	_
26	provide	_	_	VB	_	_	_	_	_
27	knowledge	_	_	NN	_	_	_	_	_
28	on	_	_	IN	_	_	_	_	_
29	how	_	_	WRB	_	_	_	_	_
30	important	_	_	JJ	_	_	_	_	_
31	processes	_	_	NNS	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	such	_	_	JJ	_	_	_	_	_
34	as	_	_	IN	_	_	_	_	_
35	instrumental	_	_	JJ	_	_	_	_	_
36	responses	_	_	NNS	_	_	_	_	_
37	to	_	_	TO	_	_	_	_	_
38	relevant	_	_	JJ	_	_	_	_	_
39	stimuli	_	_	NNS	_	_	_	_	_
40	,	_	_	,	_	_	_	_	_
41	are	_	_	VBP	_	_	_	_	_
42	influenced	_	_	VBN	_	_	_	_	_
43	by	_	_	IN	_	_	_	_	_
44	drinking	_	_	NN	_	_	_	_	_
45	patterns	_	_	NNS	_	_	_	_	_
46	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	same	_	_	JJ	_	_	_	_	_
4	line	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	Heinz	_	_	NNP	_	_	_	_	_
7	et	_	_	FW	_	_	_	_	_
8	al.	_	_	FW	_	_	_	_	_
9	conduct	_	_	VB	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	review	_	_	NN	_	_	_	_	_
12	that	_	_	WDT	_	_	_	_	_
13	starts	_	_	VBZ	_	_	_	_	_
14	with	_	_	IN	_	_	_	_	_
15	how	_	_	WRB	_	_	_	_	_
16	Pavlovian	_	_	JJ	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	instrumental	_	_	JJ	_	_	_	_	_
19	learning	_	_	NN	_	_	_	_	_
20	mechanisms	_	_	NNS	_	_	_	_	_
21	interact	_	_	VBP	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	drug	_	_	NN	_	_	_	_	_
24	addiction	_	_	NN	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	finishes	_	_	VBZ	_	_	_	_	_
27	with	_	_	IN	_	_	_	_	_
28	how	_	_	WRB	_	_	_	_	_
29	these	_	_	DT	_	_	_	_	_
30	learning	_	_	NN	_	_	_	_	_
31	mechanisms	_	_	NNS	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	their	_	_	PRP$	_	_	_	_	_
34	respective	_	_	JJ	_	_	_	_	_
35	neurobiological	_	_	JJ	_	_	_	_	_
36	correlates	_	_	NNS	_	_	_	_	_
37	can	_	_	MD	_	_	_	_	_
38	contribute	_	_	VB	_	_	_	_	_
39	to	_	_	TO	_	_	_	_	_
40	losing	_	_	VBG	_	_	_	_	_
41	versus	_	_	IN	_	_	_	_	_
42	regaining	_	_	VBG	_	_	_	_	_
43	control	_	_	NN	_	_	_	_	_
44	over	_	_	IN	_	_	_	_	_
45	drug	_	_	NN	_	_	_	_	_
46	intake	_	_	NN	_	_	_	_	_
47	.	_	_	.	_	_	_	_	_


1	Paradoxically	_	_	RB	_	_	_	_	_
2	enough	_	_	RB	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	new	_	_	JJ	_	_	_	_	_
5	technologies	_	_	NNS	_	_	_	_	_
6	do	_	_	VBP	_	_	_	_	_
7	also	_	_	RB	_	_	_	_	_
8	have	_	_	VB	_	_	_	_	_
9	their	_	_	PRP$	_	_	_	_	_
10	own	_	_	JJ	_	_	_	_	_
11	risks	_	_	NNS	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	Take	_	_	VB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	for	_	_	IN	_	_	_	_	_
4	example	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	internet	_	_	NN	_	_	_	_	_
7	gaming	_	_	NN	_	_	_	_	_
8	disorder	_	_	NN	_	_	_	_	_
9	.	_	_	.	_	_	_	_	_
10	Ryu	_	_	NNP	_	_	_	_	_
11	et	_	_	FW	_	_	_	_	_
12	al.	_	_	FW	_	_	_	_	_
13	present	_	_	VB	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	development	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	new	_	_	JJ	_	_	_	_	_
19	assessment	_	_	NN	_	_	_	_	_
20	instrument	_	_	NN	_	_	_	_	_
21	for	_	_	IN	_	_	_	_	_
22	internet	_	_	NN	_	_	_	_	_
23	addiction	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	Diagnostic	_	_	NNP	_	_	_	_	_
27	Interview	_	_	NNP	_	_	_	_	_
28	for	_	_	IN	_	_	_	_	_
29	Internet	_	_	NNP	_	_	_	_	_
30	Addiction	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	And	_	_	CC	_	_	_	_	_
2	keeping	_	_	VBG	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	mind	_	_	NN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	new	_	_	JJ	_	_	_	_	_
7	psychometric	_	_	JJ	_	_	_	_	_
8	instruments	_	_	NNS	_	_	_	_	_
9	are	_	_	VBP	_	_	_	_	_
10	also	_	_	RB	_	_	_	_	_
11	new	_	_	JJ	_	_	_	_	_
12	solutions	_	_	NNS	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	old	_	_	JJ	_	_	_	_	_
15	problems	_	_	NNS	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	Chen	_	_	NNP	_	_	_	_	_
18	et	_	_	FW	_	_	_	_	_
19	al.	_	_	FW	_	_	_	_	_
20	investigate	_	_	VB	_	_	_	_	_
21	an	_	_	DT	_	_	_	_	_
22	interesting	_	_	JJ	_	_	_	_	_
23	phenomenon	_	_	NN	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	addiction	_	_	NN	_	_	_	_	_
26	:	_	_	:	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	intensity	_	_	NN	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	memory	_	_	NN	_	_	_	_	_
31	addiction	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	They	_	_	PRP	_	_	_	_	_
2	present	_	_	VBP	_	_	_	_	_
3	us	_	_	PRP	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	development	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	Addiction	_	_	NNP	_	_	_	_	_
9	Memory	_	_	NNP	_	_	_	_	_
10	Intensity	_	_	NNP	_	_	_	_	_
11	Scale	_	_	NNP	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	treatment	_	_	NN	_	_	_	_	_
4	area	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	this	_	_	DT	_	_	_	_	_
7	special	_	_	JJ	_	_	_	_	_
8	issue	_	_	NN	_	_	_	_	_
9	offers	_	_	VBZ	_	_	_	_	_
10	an	_	_	DT	_	_	_	_	_
11	interesting	_	_	JJ	_	_	_	_	_
12	combination	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	modalities	_	_	NNS	_	_	_	_	_
15	:	_	_	:	_	_	_	_	_
16	newly	_	_	RB	_	_	_	_	_
17	designed	_	_	VBN	_	_	_	_	_
18	pharmaceutical	_	_	JJ	_	_	_	_	_
19	compounds	_	_	NNS	_	_	_	_	_
20	(	_	_	-LRB-	_	_	_	_	_
21	nalmefene	_	_	NN	_	_	_	_	_
22	)	_	_	-RRB-	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	naturally	_	_	RB	_	_	_	_	_
25	occurring	_	_	VBG	_	_	_	_	_
26	psychoactive	_	_	JJ	_	_	_	_	_
27	substances	_	_	NNS	_	_	_	_	_
28	(	_	_	-LRB-	_	_	_	_	_
29	cannabidiol	_	_	NN	_	_	_	_	_
30	)	_	_	-RRB-	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	non-pharmacological	_	_	JJ	_	_	_	_	_
34	,	_	_	,	_	_	_	_	_
35	biological	_	_	JJ	_	_	_	_	_
36	therapies	_	_	NNS	_	_	_	_	_
37	(	_	_	-LRB-	_	_	_	_	_
38	rTMS	_	_	NN	_	_	_	_	_
39	)	_	_	-RRB-	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_
41	Barrio	_	_	NNP	_	_	_	_	_
42	et	_	_	FW	_	_	_	_	_
43	al.	_	_	FW	_	_	_	_	_
44	report	_	_	VB	_	_	_	_	_
45	the	_	_	DT	_	_	_	_	_
46	main	_	_	JJ	_	_	_	_	_
47	effectiveness	_	_	NN	_	_	_	_	_
48	analysis	_	_	NN	_	_	_	_	_
49	of	_	_	IN	_	_	_	_	_
50	a	_	_	DT	_	_	_	_	_
51	phase-IV	_	_	NN	_	_	_	_	_
52	study	_	_	NN	_	_	_	_	_
53	conducted	_	_	VBN	_	_	_	_	_
54	among	_	_	IN	_	_	_	_	_
55	alcohol	_	_	NN	_	_	_	_	_
56	dependent	_	_	JJ	_	_	_	_	_
57	outpatients	_	_	NNS	_	_	_	_	_
58	taking	_	_	VBG	_	_	_	_	_
59	nalmefene	_	_	NN	_	_	_	_	_
60	,	_	_	,	_	_	_	_	_
61	the	_	_	DT	_	_	_	_	_
62	only	_	_	RB	_	_	_	_	_
63	approved	_	_	VBN	_	_	_	_	_
64	medication	_	_	NN	_	_	_	_	_
65	for	_	_	IN	_	_	_	_	_
66	alcohol	_	_	NN	_	_	_	_	_
67	reduction	_	_	NN	_	_	_	_	_
68	aims	_	_	NNS	_	_	_	_	_
69	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	use	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	rTMS	_	_	NN	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	presented	_	_	VBN	_	_	_	_	_
7	by	_	_	IN	_	_	_	_	_
8	Cardullo	_	_	NNP	_	_	_	_	_
9	et	_	_	FW	_	_	_	_	_
10	al.	_	_	FW	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	sample	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	cocaine	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	gambling	_	_	NN	_	_	_	_	_
18	patients	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	stimulation	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	left	_	_	JJ	_	_	_	_	_
6	dorsolateral	_	_	JJ	_	_	_	_	_
7	prefrontal	_	_	JJ	_	_	_	_	_
8	cortex	_	_	NN	_	_	_	_	_
9	yields	_	_	VBZ	_	_	_	_	_
10	promising	_	_	JJ	_	_	_	_	_
11	results	_	_	NNS	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	Finally	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	Batalla	_	_	NNP	_	_	_	_	_
4	et	_	_	FW	_	_	_	_	_
5	al.	_	_	FW	_	_	_	_	_
6	review	_	_	VB	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	potential	_	_	JJ	_	_	_	_	_
9	use	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	cannabidiol	_	_	NN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	addictive	_	_	JJ	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	comorbid	_	_	JJ	_	_	_	_	_
16	psychotic	_	_	JJ	_	_	_	_	_
17	disorders	_	_	NNS	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	pointing	_	_	VBG	_	_	_	_	_
20	to	_	_	TO	_	_	_	_	_
21	a	_	_	DT	_	_	_	_	_
22	prominent	_	_	JJ	_	_	_	_	_
23	role	_	_	NN	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	treatment	_	_	NN	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	cannabis	_	_	NN	_	_	_	_	_
29	addiction	_	_	NN	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	Scientific	_	_	JJ	_	_	_	_	_
2	advances	_	_	NNS	_	_	_	_	_
3	and	_	_	CC	_	_	_	_	_
4	new	_	_	JJ	_	_	_	_	_
5	technologies	_	_	NNS	_	_	_	_	_
6	are	_	_	VBP	_	_	_	_	_
7	providing	_	_	VBG	_	_	_	_	_
8	new	_	_	JJ	_	_	_	_	_
9	tools	_	_	NNS	_	_	_	_	_
10	that	_	_	WDT	_	_	_	_	_
11	let	_	_	VBP	_	_	_	_	_
12	us	_	_	PRP	_	_	_	_	_
13	expand	_	_	VB	_	_	_	_	_
14	our	_	_	PRP$	_	_	_	_	_
15	knowledge	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	improve	_	_	VB	_	_	_	_	_
19	diagnosis	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	treatment	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	addictive	_	_	JJ	_	_	_	_	_
24	behaviors	_	_	NNS	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	presenting	_	_	VBG	_	_	_	_	_
27	us	_	_	PRP	_	_	_	_	_
28	with	_	_	IN	_	_	_	_	_
29	opportunity	_	_	NN	_	_	_	_	_
30	for	_	_	IN	_	_	_	_	_
31	success	_	_	NN	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	giving	_	_	VBG	_	_	_	_	_
34	people	_	_	NNS	_	_	_	_	_
35	back	_	_	RP	_	_	_	_	_
36	their	_	_	PRP$	_	_	_	_	_
37	health	_	_	NN	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_

